Skip to main content
Premium Trial:

Request an Annual Quote

Regulus, UCSD Partner on miRNA for Angiogenic Diseases

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Regulus Therapeutics today announced it is collaborating with researchers at the University of California, San Diego School of Medicine to develop treatments for angiogenic disease using microRNA therapeutics.

The collaboration combines Regulus' miRNA platform with UCSD's expertise in animal models of angiogenesis. The collaboration recently received a UC Discovery Grant that promotes work between the university's researchers and industry.

Financial terms of the grant were not disclosed.

David Cheresh, professor of pathology at the UCSD School of Medicine and principal investigator on the grant, said in a statement that research by his colleagues and him suggest miRNA-132 may be a novel angiogenic switch that turns on angiogenesis in quiescent endothelial cells and that it may be a target for decreasing blood vessel formation.

"The object of our collaborative work with Regulus is to advance these initial discoveries and discover additional microRNAs involved in angiogenic diseases," Cheresh said.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.